DMPK Consultancy
Working closely with drug discovery teams across the pharmaceutical, biotech, CRO and academic sectors, Richard provides DMPK consultancy support and advice, helping companies progress new drugs to market.
- Human PK and dose prediction
- Critical Physicochemical and DMPK/ADME review of Hit compounds, Lead compounds, short-listed late-stage compounds and Candidate Drugs. Helping to provide the answers to:
- Could this compound have the potential to be a drug?
- What parameter(s) do I need to improve upon?
- Is my series fatally flawed?
- Key focus on converting all relevant data to unbound concentrations.
- This includes in vitro and in vivo pharmacology data in addition to the DMPK data
- in vitro – in vivo extrapolation (IVIV-E) and in vitro – in vivo correlation (IVIV-C).
- Helping to understand if we can predict the pre-clinical in vivo clearance from in vitro data
- Separate pre-clinical and human allometric approach of clearance, volume of distribution and T½ predictions
- DMPK and physicochemical gap analysis
- Critical review of screening cascade, with particular reference to the Extended Clearance Classification System (ECCS)
- Designing a Candidate Target Profile
- Drug-Drug Interaction (DDI) assessment from both a “victim” and a “perpetrator” angle
- Safety Margin estimation
- Optimising oral bioavailability
